Fulcrum Therapeutics (FULC.Q) announced positive results today from its ongoing Phase 1 trial with FTX-6058 in healthy adult volunteers. “We are very pleased with the interim results from this…
Latest News
Standard Uranium (STND.V) looks to add to Sun Dog’s uranium history
Top 5 Gainers and Losers: SEI.V, LAB.V, NCU.TO
West High Yield Resources (WHY.V) announces milestone for Magnesium Project
Top 5 Gainers and Losers: GXU.V, SANU.CN, BTR.V
Are stock markets about to crash hard?
Revive Therapeutics (RVV.CN) announces FDA acceptance of meeting request